Trial Profile
A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms VELIA; VELIA/GOG-3005
- Sponsors AbbVie
- 12 Jan 2024 This trial has been completed in Denmark, according to the European Clinical Trials Database record.
- 02 Dec 2023 This trial has been completed in Poland, according to the European Clinical Trials Database record.
- 25 Oct 2023 Status changed from active, no longer recruiting to discontinued.